Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

759 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activin receptor antagonists for cancer-related anemia and bone disease.
Fields SZ, Parshad S, Anne M, Raftopoulos H, Alexander MJ, Sherman ML, Laadem A, Sung V, Terpos E. Fields SZ, et al. Among authors: terpos e. Expert Opin Investig Drugs. 2013 Jan;22(1):87-101. doi: 10.1517/13543784.2013.738666. Epub 2012 Nov 6. Expert Opin Investig Drugs. 2013. PMID: 23127248 Review.
Sclerostin: a possible target for the management of cancer-induced bone disease.
Gkotzamanidou M, Dimopoulos MA, Kastritis E, Christoulas D, Moulopoulos LA, Terpos E. Gkotzamanidou M, et al. Among authors: terpos e. Expert Opin Ther Targets. 2012 Aug;16(8):761-9. doi: 10.1517/14728222.2012.697154. Epub 2012 Jul 5. Expert Opin Ther Targets. 2012. PMID: 22762409 Review.
Sotatercept in patients with osteolytic lesions of multiple myeloma.
Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R, Knight R, Srinivasan S, Terpos E. Abdulkadyrov KM, et al. Among authors: terpos e. Br J Haematol. 2014 Jun;165(6):814-23. doi: 10.1111/bjh.12835. Epub 2014 Mar 21. Br J Haematol. 2014. PMID: 24650009 Free PMC article. Clinical Trial.
The potential of proteasome inhibitors in cancer therapy.
Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O. Sterz J, et al. Among authors: terpos e. Expert Opin Investig Drugs. 2008 Jun;17(6):879-95. doi: 10.1517/13543784.17.6.879. Expert Opin Investig Drugs. 2008. PMID: 18491989 Review.
Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M, Terpos E. Gavriatopoulou M, et al. Among authors: terpos e. Expert Opin Ther Targets. 2009 Jul;13(7):839-48. doi: 10.1517/14728220903025770. Expert Opin Ther Targets. 2009. PMID: 19530987 Review.
Pathogenesis and management of myeloma bone disease.
Christoulas D, Terpos E, Dimopoulos MA. Christoulas D, et al. Among authors: terpos e. Expert Rev Hematol. 2009 Aug;2(4):385-98. doi: 10.1586/ehm.09.36. Expert Rev Hematol. 2009. PMID: 21082944 Review.
Management of bone disease in multiple myeloma.
Terpos E, Berenson J, Raje N, Roodman GD. Terpos E, et al. Expert Rev Hematol. 2014 Feb;7(1):113-25. doi: 10.1586/17474086.2013.874943. Epub 2014 Jan 16. Expert Rev Hematol. 2014. PMID: 24433088 Review.
Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M, Dimopoulos MA, Kastritis E, Terpos E. Gavriatopoulou M, et al. Among authors: terpos e. Expert Rev Hematol. 2017 Mar;10(3):217-228. doi: 10.1080/17474086.2017.1283213. Epub 2017 Jan 29. Expert Rev Hematol. 2017. PMID: 28092987 Review.
759 results